摘要: In 2001 valganciclovir was approved by the FDA for treatment of HIV associated retinitis and in 2003 prevention post transplant CMV. This review provides an update on status its use areas controversy: How long should prophylaxis be given?; What is appropriate dose prophylaxis?; Can it used children, at what dose?; to treat CMV disease? The question optimal dosing will probably not settled as sample size controlled trials would prohibitive. Other clearly show that extended therapy added benefit, drug safe has been identified children oral disease effective.
cabdirect.org
blackwell-synergy.com参考文章(29)
A. Caldés, S. Gil-Vernet, Y. Armendariz, H. Colom, L. Pou, J. Niubó, L. Lladó, J. Torras, N. Manito, G. Rufí, J.M. Grinyó, Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics Transplant Infectious Disease. ,vol. 12, pp. 204- 212 ,(2009) , 10.1111/J.1399-3062.2009.00481.X
M.D. Pescovitz, R.B. Ettenger, C.F. Strife, J.R. Sherbotie, S.E. Thomas, S. McDiarmid, S. Bartosh, J. Ives, M.R. Bouw, J. Bucuvalas, Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transplant Infectious Disease. ,vol. 12, pp. 195- 203 ,(2009) , 10.1111/J.1399-3062.2009.00478.X
Alden M. Doyle, Karen M. Warburton, Simin Goral, Emily Blumberg, Robert A. Grossman, Roy D. Bloom, 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation. ,vol. 81, pp. 1106- 1111 ,(2006) , 10.1097/01.TP.0000204048.90367.97
Brenda S. Clark, I-Fen Chang, Saul J. Karpen, Lydia Herrera, Jaymee D. Scott, Lisa J. Bristow, Rubén E. Quirós-Tejeira, John A. Goss, Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation. ,vol. 77, pp. 1480- 1480 ,(2004) , 10.1097/01.TP.0000123081.81022.33
Jennifer Vethamuthu, Janusz Feber, Ann Chretien, Dagmar Lampe, Guido Filler, Unexpectedly high inter‐ and intrapatient variability of Ganciclovir levels in children Pediatric Transplantation. ,vol. 11, pp. 301- 305 ,(2007) , 10.1111/J.1399-3046.2006.00669.X
Andre C. Kalil, Alison G. Freifeld, Elizabeth R. Lyden, Julie A. Stoner, Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and Efficacy PLoS ONE. ,vol. 4, pp. e5512- ,(2009) , 10.1371/JOURNAL.PONE.0005512
Wei Zhao, Véronique Baudouin, Daolun Zhang, Georges Deschênes, Chantal Le Guellec, Evelyne Jacqz-Aigrain, Population Pharmacokinetics of Ganciclovir Following Administration of Valganciclovir in Paediatric Renal Transplant Patients Clinical Pharmacokinectics. ,vol. 48, pp. 321- 328 ,(2009) , 10.2165/00003088-200948050-00004
A Asberg, A Humar, AG Jardine, H Rollag, MD Pescovitz, H Mouas, A Bignamini, H Toöz, I Dittmer, M Montejo, A Hartmann, VICTOR Study Group, None, Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. American Journal of Transplantation. ,vol. 9, pp. 1205- 1213 ,(2009) , 10.1111/J.1600-6143.2009.02617.X
Daniel C. Brennan, Kathy A. Garlock, Gary G. Singer, Mark A. Schnitzler, Bruce J. Lippmann, Richard S. Buller, Monique Gaudreault-Keener, Jeffrey A. Lowell, Surendra Shenoy, Todd K. Howard, Gregory A. Storch, Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation. ,vol. 64, pp. 1843- 1846 ,(1997) , 10.1097/00007890-199712270-00036
Nancy Perrottet, Laurent A. Decosterd, Pascal Meylan, Manuel Pascual, Jerome Biollaz, Thierry Buclin, Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clinical Pharmacokinectics. ,vol. 48, pp. 399- 418 ,(2009) , 10.2165/00003088-200948060-00006